Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease
暂无分享,去创建一个
Y. Yazaki | Y. Tanaka | Y. Kanda | M. Kami | K. Mitani | K. Izutsu | H. Hirai | S. Chiba | K. Izutsu | K. Yuji | H. Honda | T. Asai | S. Ogawa | N. Nakamura | K. Shirakawa | T. Saito | Yuji Tanaka | T. Yatomi | N. Nakamura | Y. Yazaki
[1] S. Nagata,et al. Downregulation of Fas ligand by shedding , 1998, Nature Medicine.
[2] J.W. Lee,et al. Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD , 1997, Bone Marrow Transplantation.
[3] K. Yoshino,et al. A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice. , 1997, Blood.
[4] K. Elkon,et al. A major role for the Fas pathway in acute graft-versus-host disease. , 1996, Journal of immunology.
[5] E. Podack,et al. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice , 1996, The Journal of experimental medicine.
[6] A. H. Drummond,et al. Fas ligand in human serum , 1996, Nature Medicine.
[7] K. Akashi,et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. , 1996, Bone marrow transplantation.
[8] J. Tschopp,et al. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease , 1996, The Journal of experimental medicine.
[9] A. Kawasaki,et al. Metalloproteinase-mediated release of human Fas ligand , 1995, The Journal of experimental medicine.
[10] S. Nagata,et al. The Fas death factor , 1995, Science.
[11] J. Inazawa,et al. Human Fas ligand: gene structure, chromosomal location and species specificity. , 1994, International immunology.
[12] P. Golstein,et al. T cell receptor‐induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A , 1994, European journal of immunology.
[13] P. Tiberghien,et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. , 1992, Blood.
[14] P. Tiberghien,et al. Soluble CD8, IL-2 receptor, and tumor necrosis factor-alpha levels in steroid-resistant acute graft-versus-host disease. Relation with subsequent response to anti-IL-2 receptor monoclonal antibody treatment. , 1991, Transplantation.
[15] J. Bergerat,et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10) , 1990, Blood.
[16] J. Sprent,et al. Lethal graft-versus-host disease across minor histocompatibility barriers in mice. , 1983, Clinics in haematology.
[17] G. Janossy,et al. USE OF ANTI-T-CELL MONOCLONAL ANTIBODY OKT3 TO PREVENT ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE LEUKAEMIA , 1982, The Lancet.
[18] J. Sprent,et al. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow , 1978, The Journal of experimental medicine.
[19] K. Oshimi,et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. , 1998, Blood.
[20] K. Koretz,et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. , 1993, Laboratory investigation; a journal of technical methods and pathology.
[21] T. Strom,et al. Anti-Interleukin-2 Receptor Monoclonal Antibody Treatment Prolongs Allograft Survival , 1986 .